Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects.

Shang DW, Wang ZZ, Hu HT, Zhang YF, Ni XJ, Lu HY, Zhang M, Hu JQ, Qiu C, Peng H, Shen LF, Wen YG.

Eur J Clin Pharmacol. 2018 Jan;74(1):61-67. doi: 10.1007/s00228-017-2340-1. Epub 2017 Oct 3.

PMID:
28975417
2.

Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs.

Swathy B, Saradalekshmi KR, Nair IV, Nair C, Banerjee M.

Epigenomics. 2017 Jun;9(6):811-821. doi: 10.2217/epi-2016-0181. Epub 2017 Apr 21.

PMID:
28429622
3.

Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.

Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K.

Int J Neuropsychopharmacol. 2017 Jul 1;20(7):529-537. doi: 10.1093/ijnp/pyx019.

4.

Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.

Akamine Y, Sugawara-Kikuchi Y, Uno T, Shimizu T, Miura M.

Ann Clin Biochem. 2017 Nov;54(6):677-685. doi: 10.1177/0004563216686377. Epub 2017 Feb 8.

PMID:
27932669
5.

Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.

Greenberg WM, Citrome L.

Clin Pharmacokinet. 2017 May;56(5):493-503. doi: 10.1007/s40262-016-0465-5. Review.

PMID:
27722855
6.

Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.

Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K.

Int J Neuropsychopharmacol. 2016 Dec 30;19(12). pii: pyw083. doi: 10.1093/ijnp/pyw083. Print 2016 Dec.

7.

Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine.

Akamine Y, Uehara H, Miura M, Yasui-Furukori N, Uno T.

J Clin Pharm Ther. 2015 Aug;40(4):480-2. doi: 10.1111/jcpt.12286. Epub 2015 May 26.

PMID:
26009790
8.

The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.

van der Weide K, van der Weide J.

J Clin Psychopharmacol. 2015 Jun;35(3):228-36. doi: 10.1097/JCP.0000000000000319.

PMID:
25868121
9.

Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition.

Hamaguchi W, Masuda N, Miyamoto S, Shiina Y, Kikuchi S, Mihara T, Moriguchi H, Fushiki H, Murakami Y, Amano Y, Honbou K, Hattori K.

Bioorg Med Chem. 2015 Jan 15;23(2):297-313. doi: 10.1016/j.bmc.2014.11.039. Epub 2014 Dec 3.

PMID:
25515954
10.

Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.

Suzuki T, Mihara K, Nakamura A, Kagawa S, Nagai G, Nemoto K, Kondo T.

Ther Drug Monit. 2014 Oct;36(5):651-5. doi: 10.1097/FTD.0000000000000070.

PMID:
24682161
11.

Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.

Kim KA, Joo HJ, Lee HM, Park JY.

Pharmacogenet Genomics. 2014 Jan;24(1):35-42. doi: 10.1097/FPC.0000000000000020.

PMID:
24240480
12.

Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.

Blobaum AL, Bridges TM, Byers FW, Turlington ML, Mattmann ME, Morrison RD, Mackie C, Lavreysen H, Bartolomé JM, Macdonald GJ, Steckler T, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR, Daniels JS.

Drug Metab Dispos. 2013 Dec;41(12):2066-75. doi: 10.1124/dmd.113.052662. Epub 2013 Sep 3.

13.

A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.

Potkin SG, Preskorn S, Hochfeld M, Meng X.

J Clin Psychopharmacol. 2013 Feb;33(1):3-10. doi: 10.1097/JCP.0b013e31827c0314.

PMID:
23277250
14.

Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.

Andrade C.

J Clin Psychiatry. 2012 Nov;73(11):e1362-4. doi: 10.4088/JCP.12f08200. No abstract available.

15.

Modafinil and armodafinil in schizophrenia.

Andrade C.

J Clin Psychiatry. 2012 Aug;73(8):e1062-4. doi: 10.4088/JCP.12f07977. No abstract available.

16.

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

Bigos KL, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR.

Mol Psychiatry. 2011 Jun;16(6):620-5. doi: 10.1038/mp.2011.38. Epub 2011 Apr 26.

17.

Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.

Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W, Boonleang J, Wongnawa M, Rujimamahasan N, Pipatrattanaseree W.

J Clin Pharm Ther. 2012 Apr;37(2):221-5. doi: 10.1111/j.1365-2710.2011.01271.x. Epub 2011 Apr 26.

PMID:
21518375
18.

Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes.

Mas S, Gassò P, Alvarez S, Parellada E, Bernardo M, Lafuente A.

Pharmacogenomics J. 2012 Jun;12(3):255-9. doi: 10.1038/tpj.2010.91. Epub 2010 Dec 21.

PMID:
21173786
19.

Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders.

Gassó P, Mas S, Alvarez S, Trias G, Bioque M, Oliveira C, Bernardo M, Lafuente A.

Pharmacogenomics. 2010 Dec;11(12):1725-31. doi: 10.2217/pgs.10.158.

PMID:
21142916
20.

Schizophrenia and obsessive-compulsive disorder.

Devulapalli K, Nasrallah HA.

Am J Psychiatry. 2010 Nov;167(11):1407-8. doi: 10.1176/appi.ajp.2010.10081111. No abstract available.

PMID:
21041254

Supplemental Content

Loading ...
Support Center